Affordable Access

Access to the full text

Psychedelic microdosing benefits and challenges: an empirical codebook

Authors
  • Anderson, Thomas1
  • Petranker, Rotem2
  • Christopher, Adam3
  • Rosenbaum, Daniel4
  • Weissman, Cory4
  • Dinh-Williams, Le-Anh5
  • Hui, Katrina4
  • Hapke, Emma4
  • 1 University of Toronto, Department of Psychology, Mississauga, Canada , Mississauga (Canada)
  • 2 York University, Clinical Psychology, Toronto, Canada , Toronto (Canada)
  • 3 University of Toronto, Department of Medicine, Toronto, Canada , Toronto (Canada)
  • 4 University of Toronto, Department of Psychiatry, Toronto, Canada , Toronto (Canada)
  • 5 University of Toronto at Scarborough, Department of Psychological Clinical Science, Toronto, Canada , Toronto (Canada)
Type
Published Article
Journal
Harm Reduction Journal
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jul 10, 2019
Volume
16
Issue
1
Identifiers
DOI: 10.1186/s12954-019-0308-4
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundMicrodosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized.MethodsIn the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers.ResultsWe describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report.ConclusionsThese mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come.

Report this publication

Statistics

Seen <100 times